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Abstract
Plasmid DNA vaccines are being developed for many human and animal diseases
with some notable success, however, the formulations of these vaccines need to be
adjusted to provide a more immunogenic effect with a practical dose volume. The
approach to this problem adopted in this study is targeting the DNA vaccine to antigen
presenting cells (APCs) through a pathway that stimulates the induction ofa CD8+ T cell
based immune response. An anti-DNA antibody is employed to selectively deliver the
plasmid to APCs via their antibody-binding Fc receptors. It is hoped that the antibodyDNA complex vaccine will outperform the DNA alone in increasing uptake and
expression of Herpes Simplex Virus antigen, thereby leading to a more robust immune
response.

Introduction
Conventional vaccines have been successful in stimulating humoral immune
responses against many diseases, but it has been found that stimulating a CDS+ T cell
(a.k.a. Cytotoxic T lymphocyte or CTL) mediated immune response with a vaccine that is
both safe and effective often proves to be a greater challenge. In the case of intracellular
parasites and some viruses such as Herpes Simplex Virus-1 (HSV -1), an antibody based
response is not sufficient for protection; a CD8+ T cell based response is necessary. The
worldwide prevalence of lethal diseases for which no effective vaccine is yet available
have stimulated creative new approaches to vaccinology, such as plasmid DNA
vaccination. The benefits of the DNA vaccine approach include an increased safety
profile (due to the fact that no live virus is used) and the ability to stimulate a CD8+ T cell
response to the specific proteins of interest. The major drawback at this point in time is
its relative inefficiency. Impractical volumes are required in order to stimulate a fully
protective immune response. The current focus is on increasing immunogenicity so that
these vaccines can one day be used in humans.
DNA vaccination utilizes a plasmid encoding a gene for an antigenic protein
under the control of a strong viral promoter, such as the CMV promoter. DNA vaccines
work on the premise that the plasmid is taken up into cells, transcribed, and translated
into protein that can then be processed and presented on MHC Class I molecules for
activation of CD8+ T cells. With few exceptions, all cells in the body process and present
peptides made inside the cell on MHC Class I, and in fact, this is how virally infected
cells are identified. Professional antigen presenting cells (APCs) are specially equipped to
activate the immune system both through the MHC Class I dependant pathway described

above as well as through an exogenous protein (MHC Class II) processing pathway.
APCs are designed to prime the immune system, and express costimulatory surface
molecules and secrete inflammatory cytokines to that end. Giving the cells a plasmid
DNA blueprint for viral protein makes the cell appear to be infected by that virus,
stimulating an immune response.
The first hint that such an approach might be feasible came in 1990 when it was
shown that injection of naked DNA into skeletal muscle lead to in vivo expression of the
encoded protein for up to two months [1]. Later, other groups successfully used this
strategy for immunizations in mice [2,3]. Ulmer's group provided protection from
influenza by administering a plasmid encoding Influenza A nucleoprotein, then
challenging with a different strain ofInfluenza A [3]. This is remarkable even today.
HSV -1 infection is notoriously difficult to prevent with vaccination. Many
approaches center around administering the HSV -1 glycoprotein B (gB) or genes
encoding it in plasmid DNA vectors. gB contains major CD8+ T cell and CD4+ T cell
epitopes. In the C57B1I6 mouse, we know that the major CD8+ T cell epitope is gB498-505
and has the sequence SSIEF ARL. Whether administered exogenously or produced in the
vaccine transfected cell, gB is then processed down to various peptide epitopes, including
SSIEF ARL. It has been shown in a similar system that administering the SSIEF ARL
epitope can in fact stimulate a CD8+ T cell response and that a CTL response directed
against just one epitope can protect against HSV-2 challenge [4]. Studies from our own
group have found that gB encoding plasmid vaccines coadministered with DNA encoding
IL-12 or IL-18 improves protection against a lethal Herpes Simplex Virus-1 challenge
[5]. IL-12 and IL-18 are cytokines which polarize the immune response toward a Th1

dominated, cell mediated (CTL) response rather than a Th2 humoral (antibody based)
immune response. Additionally, other members have speculated that the addition of
genes encoding IL-15 and/or IL-23, critical cytokines involved in the maintenance of
memory T cells, may boost the level of memory CD8+ T cells [6]. Furthermore, other
members of our lab have demonstrated that including DNA containing CpG sequences
into a peptide vaccine induces CD8+ T cell based immunity and resistance to viral
challenge [7]. CpG sequences are unmethylated bacterial DNA stretches which activate
pattern recognition molecules, namely TLR-9, on APCs stimulating them to produce a
more robust killer cell based response. In this case, we see that certain DNA can itself
serve as an adjuvant.
The study outlined in this paper seeks to prove the hypothesis that complexing
plasmid DNA to an anti-DNA antibody will provide more efficient targeting ofthe
vaccine to APCs, leading to increased uptake and expression of viral antigen and
therefore a more robust immune response when compared to the plasmid DNA
administered alone. APCs express Fc receptors on their cell surface which serve the
purpose of bringing antibody-bound molecules into the cell for processing and
presentation (Figure 1). We wish to exploit this mechanism to target the vaccine to APCs
and achieve the goals described above.

Materials and Methods
Mice

Four- to five-week-old C57BLl6 (H_2 b ) mice were purchased from Harlan
Sprague-Dawley (Indianapolis, IN). In conducting the research described in this work we

adhered to the Guide for the Care and Use of Laboratory Animals as proposed by the
committee on care of Laboratory Animal Resources Commission on Life Sciences of the
National Research Council. The facilities are fully accredited by the American
Association for Accreditation of Laboratory Animal Care.

Peptides
The HSV gB (amino acids 498 to 505) peptide SSIEFARL and the chicken
ovalbumin (aa 257 to 264) peptide SIINFEKL were synthesized and supplied by
Research Genetics (Huntsville, AL)

Cell lines

Vero (African green monkey kidney cell line) was used for growing of viral
stocks and MC38 was used as a target cell (C57BLl6 adenocarcinoma, H_2

b

).

All cell

lines were cultured in Dulbecco's Modification of Eagle's Medium (Mediatech, VA)
supplemented with 10% heat-inactivated fetal bovine serum, 5 mglL of gentamicin
sulfate, and 2 mM L-glutamine. T cell stimulation assays were carried out in 25 mM
Hepes buffered RPMI-1640 media (Sigma, St. Louis, MO) containing 10% heatinactivated fetal bovine serum, 5 mglL of gentamicin sulfate, 0.05 mM 2-ME, and 2 mM
L-glutamine.

MRSS-I production and purification

MRSS-1 is a B cell hybridoma which makes a mouse IgG3 isotype anti-DNA
antibody (ATCC, Manassas, VA) [8]. The hybridoma was grown in roller bottles in

DMEM 5% FCS (Mediatech, Herndon, VA and Hyclone, Logan, UT, respectively). The
cells were centrifuged out, then the supernatant was filtered using Whatman paper
(Middlesex, UK) and was frozen at -20°C until a later date. The supernatant was then
thawed and mixed 1: I with a saturated ammonium sulfate solution and allowed to sit at
4°C overnight for precipitation of immunoglobulins and other high-molecular weight
proteins. The precipitated proteins were passed over a protein L column (Pierce,
Rockford IL) to isolate mouse Ig by affinity chromatography. The concentration of the
antibody was determined by UV spectroscopy.

Plasmid DNA preparation

The plasmid pcDNA-gB was created as described by Manickan et al.[9]. It was
propagated in E. coli DH5-a cells and grown in LB broth (both Invitrogen, San Diego,
CA) and purified with an Endofree Plasmid Mega kit (Qiagen, Valencia, CA).

DNA/Antibody binding assay

pcDNA-gB was bound to a standard ELISA plate (Coming, Acton, MA) at
[DNA]=5

~g/ml,

IOOul/well using ReactiBind (Pierce, Rockford, IL) to bind the DNA to

the plate. MRSS-I was then added at various concentrations. Negative control wells
contained non-specific mouse IgG (Southern Biotech Associates, Birmingham, AL). All
wells were done in duplicate and the ELISA was performed as previously described [9].

T cell activation assay

An in vitro T cell activation assay was performed by first allowing splenic
adherent cells (splenocytes adhered to plastic tissue culture plates for 2 h @ 37°C and
then washed, scraped, and counted), consisting mainly of macrophage and DC, to take up
plasmid DNA (pcDNA-gB), express protein, and present processed peptides to T cells.
Antigen sources were as follows: O.lllg/ml ofMRSS-l anti-DNA antibody was
incubated with O.1llg/ml ofpcDNA-gB for 1 h @ 37°C (total vol 100 Ill). This complex
was then added to 500,000 (total vol 50 Ill) splenic adherent cells in a 96 well U-bottom
plate and allowed to incubate for 24 h 37°C, 5% C02. Plasmid DNA without antibody as
well as a group with an irrelavent control antibody were also included. For a positive
control adherent splenocytes were either transfected with the same amount ofpcDNA-gB
as above using Lipofectamine 2000 according to the manufacturer's instructions
(Invitrogen), or gB498-505 peptide (lllg/ml) was used. Following the 24 h incubation
50, 000 (total vol 50 Ill) T cell hybridoma specific for gB498-505, clone 2E2 [10]
(provided by F. Carbone) were added and the incubation was continued for another 24 h.
Supernatant was then collected and tested for IL-2 production by ELISA.

ELISPOT

ELI SPOT assay for IFN -y secreting cells was performed as previously described
[7], except for slight modifications. Briefly, 96-well filter plates (Millipore HA) were
coated with capture antibody for IFN-y (RA-6A2) (BD Pharmingen) ON @ 4°C (BD
Pharmingen) (2 Ilg/ml) in PBS. Plates were then washed with sterile PBS and blocked

with culture media containing 10% FCS. Splenocytes from a single cell suspension were
incubated at various effector:stimulator ratios. 105 irradiated, SIINFEKL or SSIEF ARLpulsed irradiated (3000 rads), syngeneic splenocytes were used as stimulators. Serial 2fold dilutions of effectors were then incubated with stimulators starting with 5 x 105 and
ending with 6.25 x 104 • 20 U/well oflL-2 was also added to the culture. Cells were then
incubated for 48 h at 37°C, 5% C02. Wells were then washed with PBS, followed by
PBS-Tween. Biotin anti-mouse IFN-y (XMG1.2) (BD Pharmingen) (1 ).!g/ml in PBS 3%
BSA) was then added to each well and incubated ON @ 4°C. Wells were then washed
with PBS-Tween and streptavidin-conjugated peroxidase (Jackson Laboratories, Bar
Harbor, ME) in PBS 3% BSA was added to each well (1 ).!g/ml) for 30 min @ 37°C.
Wells were then washed with PBS-Tween and developed using 3-amino-9-ethylcarbazole
(AEC) (Sigma) in 0.1 M acetate buffer pH 5.0, containing 0.05% H202. Reactions were
allowed to proceed for 10 min and were ended by extensive washing with dH 20. Plates
were allowed to dry and then counted on a stereo microscope.

CTL assay

The CTL assay was performed as described earlier [7]. Briefly, effector cells
generated after a 5 d in vitro expansion (with SSIEFARL-Ioaded, irradiated splenocytes)
were analyzed for their ability to kill major histocompatibility complex (MHC)-matched
antigen-presenting targets (H-2

b
).

The cells were mixed with the target at various ratios

and incubated for 4 h. The targets included 51Cr-pulsed MHC-matched SSIEF ARL-pulsed
as well as control SIINFEKL-pulsed MC38 target cells. Percent specific lysis was then
calculated according to the following formula:

100 x [(experimental release - spontaneous release)/ (maximum release - spontaneous
release)].

ELISA
ELISA was performed as previously described [7]. Briefly, 96-well EIAIRIA
plates were coated with capture antibody for IL-2 (BD Pharmingen) ON @ 4°C (2

~g/ml)

in 1 M Na2HP04. The wells were then washed with PBS-Tween and supernatant taken
after 24 h was added and the plates were incubated ON @ 4°C. For detection wells were
washed with PBS-Tween and biotin anti-mouse IL-2 (BD Pharmingen) (1

~g/ml

in PBS

3% BSA) was then added to each well and incubated for Ih @ RT. Wells were then
washed with PBS-Tween and streptavidin-conjugated peroxidase (Jackson Laboratories,
ME) in PBS 3% BSA was added to each well (1

~g/ml)

for 30 min @ RT. Plates were

then washed and developed using ABTS (Sigma). ELISA readings were taken on an
automated ELISA reader (SpectraMAX 340, Molecular Devices, Sunnyvale, CA).

Immunizations

90llg/mouse pcDNA-gB was complexed to IOllg/mouse MRSS-l for 1 h @ 37°C.
This preparation was then split in half and administered to both of the tibialis anterior
muscles of the mouse on day O. Negative controls included pcDNA-gB alone and
pcDNA-gB + control mouse IgG (Southern Biotech Associates, Birmingham, AL). Both
underwent the same incubation as the experimental preparation. Tibialis anterior
administration of 106 pfu recombinant vaccinia virus expressing gB (VV -gB) served as a
positive control.

Statistical analysis

The data were analyzed by using a 2-tailed student's t test, and p values less than

.05 were deemed significant.

Results
MRSS-l binds to the pcDNA-gB vaccine

Before using the complexed vaccine for study, it was necessary to demonstrate
that the antibody purified from MRSS-l does, in fact, bind pcDNA-gB. Following the
ELISA based binding assay protocol described above, a dose dependant binding curve
was found to exist for the MRSS-l but not for the negative control antibody (Figure 2).
Binding increased consistently up to the 1.0 f...Lg/ml antibody concentration, after which
the binding curve plateaus.

pcDNA-gB + MRSS-l activates a Tcell hybridoma specific/or the gB 498-505
SSIEFARL epitope

The T cell activation assay demonstrated that the pcDNA-gB + MRSS-l complex
vaccine was capable of stimulating a T cell hybridoma which recognizes the SSIEFARL
epitope. Moreover, the response to the pcDNA-gB + MRSS-l was three-fold higher than
that of the pcDNA-gB alone (Figure 3). Adherent splenocytes loaded with pcDNA-gB
alone secreted an amount ofIL-2 indistinguishable from background (16pg/ml) whereas
those loaded with pcDNA-gB + MRSS-l secreted an amount which is three times
background (48pg/ml IL-2). The lipofectamine and gB498-505 peptide positive controls

were included to verify that the assay worked, though it should be noted that neither is a
vaccine candidate in this study. gB 498-505 has been evaluated in other studies as a
vaccine component along with adjuvants such as heat shock proteins and alum with some
success [11][Pack, unpublished data].

pcDNA-gB + MRSS-I stimulates IFN-ysecreting cells

The ELI SPOT assay measures the relative number of activated inflammatory
cells, identified by their secretion of the inflammatory cytokine IFN-y, between treatment
groups. We observed a more than five-fold increase in the number ofIFN-y secreting
cells in the pcDNA-gB + MRSS-l group (82 ± 50 SFU) over the group which received
pcDNA-gB alone (14 ± 6 SFU). This shows that the pcDNA-gB + MRSS-l vaccine can
not only stimulate a response, it also elicits a more potent response than pcDNA-gB alone
and that this response is of the desired Thl type. This response was less robust than the
gold standard live vaccinia virus encoding gB, which gave 631 ± 273 SFU, but the live
virus vaccine has problems of its own, namely a decrease in safety.

Specific killing ofSSIEFARL loaded target cells is increased with the pcDNA -gB

+MRSS-I vaccine
When we examine the ability of splenocytes from the various groups to kill
peptide loaded target cells, we are able to quantitatively see the efficacy ofthe vaccine in
stimulating a CTL response. In this case, we saw approximately a two-fold increase in
CTL specific lysis oftarget cells in the pcDNA-gB group versus the group which
received pcDNA-gB alone (Figure 4). At an effector: target ratio of25:1, splenocytes

from pcDNA -gB + MRSS-l vaccinated mice exhibited 31 % specific killing oftarget
cells (the peak of the response curve) whereas splenocytes from pcDNA-gB vaccinated
mice exhibited only 15% specific killing. This two fold difference in responses is
consistent all the way down to a effector to target ratio of 1.5: 1. It should also be noted
that the pcDNA-gB + negative control antibody response was, at 13% specific killing at
an effector to target ratio of25:1, comparable to that of the pcDNA-gB alone all the way
down the dilution series. pcDNA-gB + MRSS-l even stood up reasonably well when
compared to the gold standard live vaccinia virus encoding gB, which exhibited 52%
specific lysis at its peak. A negative control containing all the same groups and target
cells loaded with an irrelevant negative control peptide, SIINFEKL, demonstrated the
expected negligible amount of CTL activity (data not shown).

Discussion

Various strategies are employed to increase immunogenicity or skew the response
toward Thllinflammatory and CTL mediated immunity vs. Th2lhumoral immunity. In
viruses subject to rapid mutation, multiple antigens corresponding to different strains may
be encoded, as in a recent influenza vaccine trial [12]. Genetic adjuvants (i.e. genes for
cytokines, transcription factors, growth factors, or costimulatory molecules) may be
added to enhance the response or skew it toward a Thl or Th2 bias [13]. Additionally,
CpG motifs in the plasmid DNA activate TLR-9 on plasmacytoid DCs, stimulating them
to produce type I interferons and activate NK cells [14]. Chemical adjuvants such as alum
are also often employed to increase immunogenicity by creating an "antigen depot" to
slow the release of antigen [15]. The administration of the vaccine in a "prime-boost"

strategy by following the DNA vaccine with a viral vector vaccine is another popular and
effective technique [13].
Additionally, dendritic cells (DCs), a subset of the APC population, have been
shown to mature upon binding of an immune complex to its Fc receptor, after which the
DC presents the antigen on both MHC Class I and Class II [16]. The DC is capable of
stimulating both CD8+ and cognate helper CD4+ T cell responses. APCs express higher
levels of costimulatory molecules than the average cell, making them better able to
activate CD8+ and CD4+ T cells. In light ofthis, as well as the cross-priming
phenomenon exhibited by DCs, many ofthe plasmid DNA vaccine optimization
strategies in current studies involve targeting the DNA to APCs and/or promoting an
immune response which is more cellular rather than humoral.
One such study uses a targeting protein from Reovirus to ensure that mucosally
administered DNA is targeted to M cells which deliver it to the subepithelial space; an
area of high immune cell concentration [17] [18]. Another used bacterial "ghosts"
derived from Manheim hemolytica to target encased plasmid DNA to APCs (via the
previously described exogenous pathway) and serve as natural adjuvants [19].
One important study described a method to increase targeting of a DNA vaccine
to DC by inoculating mice with a plasmid encoding an antigen-Fc fusion protein [20].
Importantly, this fusion protein, once secreted, was taken up by DC via receptor mediated
endocytosis and caused cross priming of the antigen. Typically, material obtained
exogenously is presented on MHC Class II molecules for induction of a Th2 response.
Cross priming is a phenomenon observed in DCs whereby exogenous antigens presented
in certain contexts can be presented on MHC Class I molecules for the stimulation of a

CDS+ T cell response (Figure 6). Many postulate that DC cross-priming may be an
important part of the mechanism by which DNA vaccines work to stimulate CTL
responses [21]. The cross-priming pathway gives the plasmid DNA access to the
cytoplasm for transcription, translation and processing of antigen though the MHC Class
I endogenous pathway. Seeing the success of this targeting strategy along with evidence
of the DC's importance in DNA vaccine success validated our own, which is, in essence,
a more direct use ofFc receptor mediated uptake of a vaccine into DCs.
The study described in this paper represents preliminary data that suggests that the
addition of the anti-DNA antibody MRSS-l to the pcDNA-gB vaccine improves its
immunogenicity. It can be said that all the data seems to point to an increased ability to
prime T cells in vitro, a more robust CTL response, and a larger number ofIFN-y
producing cells when MRSS-l is added to the vaccine. Further studies need to be done in
order to fully characterize and quantify the apparent improvements. It is possible that the
effect seen is not due to more effective targeting, but to the maturation effects that
immune complexes have on DCs [16]. RT-PCR could be performed on DCs in vitro to
show that expression of the gB protein is increased when the pcDNA-gB is administered
as an immune complex with MRSS-l. All the measurements of immune response shown
here should be repeated at a later time point to examine memory responses. Additionally,
the vaccine should be tested in a homologous boost and heterologous prime-boost
regimen. Finally, the best test of any vaccine is a live virus challenge experiment. This
will help to insure that the response generated is strong enough and of the correct type to
be protective against infection. This will also allow for more evaluation of the longerterm safety of the formulation.

If the vaccine were to be used in clinical veterinary or human practice, the
formulation would need to be revised to use a sequence specific antibody to avoid the
autoimmunity concerns typically associated with anti-DNA antibodies, which can cause
diseases such as systemic lupus erythematosus [22]. A suitable antibody is already
available; the Prat-Gay group has developed a hybridoma which produces antibodies
which bind only a specific DNA sequence from HPV [23]. This sequence could be added
to the plasmid DNA vaccine to give an epitope/ binding site for the antibody. As this
sequence is not present in mammalian DNA, these antibodies should display no crossreactivity with self DNA. The safety of DNA vaccines in general is still under review,
with some believing that the injection of plasmid DNA into muscle leads to
autoimmunity mediated by anti-DNA antibodies [24], where others feel that the
administration of plasmid DNA does not cause autoimmunity, but does worsen the effect
in those individuals predisposed to autoimmune disorders [25]. This study, and DNA
vaccines in general, possess genuine potential, but pose difficult questions as well, which
must be answered before these technologies can be useful to human or animal health.

Appendix: Figures
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